di Reumatologia, Società Italiana, trans. 2026. “PO:03:034 | Inhibition of Radiographic Progression With Bimekizumab Treatment Observed in BDMARD-Naïve Patients With Active Psoriatic Arthritis at 2 Years: Results from a Phase 3 Study and Its Open-Label Extension: Laura C Coates1, M Elaine Husni2, Mitsumasa Kishimoto3, Proton Rahman4, Philipp Sewerin5, Enrique R Soriano6, Barbara Ink7, Rajan Bajracharya7, Jason Coarse8, Philip J Mease9, Emanuela Mazzola10, Peter Nash11 | 1NDORMS, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust Oxford, United Kingdom; 2Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Cleveland, USA; 3Department of Nephrology and Rheumatology, Kyorin University School of Medicine Tokyo, Japan; 4Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Memorial University of Newfoundland St. Johns, Canada; 5Rheumazentrum Ruhrgebiet, University Hospital of the Ruhr University Bochum Herne Germany; 6Hospital Italiano De Buenos Aires and University Institute Hospital Italiano De Buenos Aires Buenos Aires, Argentina; 7UCB Slough, United Kingdom; 8UCB Morrisville, USA; 9Department of Rheumatology, Providence-Swedish Medical Center and University of Washington Seattle, USA; 10UCB Milan, Italy; 11School of Medicine, Griffith University, Brisbane, Australia”. Reumatismo 77 (s1). https://doi.org/10.4081/reumatismo.2025.2290.